Acute effects of Rho-kinase inhibitor fasudil on pulmonary arterial hypertension in patients with congenital heart defects

Circulation Journal

Volumn 79, Issue 6, 2015, Pages 1342-1348

  Xiao, Jia Wang ^a   Zhu, Xian Yang ^a   Wang, Qi Guang ^a   Zhang, Duan Zhen ^a   Cui, Chun Sheng ^a   Zhang, P ^a   Chen, Huo Yuan ^a   Meng, Li Li ^a  

^a GENERAL HOSPITAL OF NORTHERN THEATER COMMAND   (China)

Author keywords

Congenital heart defect; Fasudil; Hemodynamics; Pulmonary arterial hypertension; Rho kinase inhibitor

Indexed keywords

FASUDIL; 1 (5 ISOQUINOLINESULFONYL) 2 METHYLPIPERAZINE; PROTEIN KINASE INHIBITOR; RHO KINASE; VASODILATOR AGENT;

ADULT; ARTERIAL OXYGEN SATURATION; ARTICLE; BODY SURFACE; BODY WEIGHT; CLINICAL ARTICLE; CONGENITAL HEART MALFORMATION; DISEASE SEVERITY; DIZZINESS; DRUG TOLERABILITY; DYSPNEA; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW UP; FUNCTION TEST; HEADACHE; HEART CATHETERIZATION; HEART HEMODYNAMICS; HEART RATE; HEMODYNAMIC PARAMETERS; HUMAN; LUNG ARTERY PRESSURE; LUNG BLOOD FLOW; LUNG VASCULAR RESISTANCE; MALE; PULMONARY HYPERTENSION; SYSTEMIC CIRCULATION; ADOLESCENT; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; COMPLICATION; DRUG EFFECTS; HEMODYNAMICS; HYPERTENSION, PULMONARY; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; YOUNG ADULT;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ADOLESCENT; ADULT; CARDIAC CATHETERIZATION; FEMALE; HEART DEFECTS, CONGENITAL; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; RHO-ASSOCIATED KINASES; VASODILATOR AGENTS; YOUNG ADULT;

EID: 84930060994     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-14-1015     Document Type: Article

References (24)

1. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009; 34: 1219-1263.
2. Humbert M, Sitbon O, Yaici A, Montani D, O’Callaghan DS, Jais X, et al. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J 2010; 36: 549-555.
3. Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS, et al. Predicting survival in pulmonary arterial hypertension: In-sights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010; 122: 164-172.
4. Gorenflo M, Gu H, Xu Z. Peri-operative pulmonary hypertension in paediatric patients: Current strategies in children with congenital heart disease. Cardiology 2010; 116: 10-17.
5. Tamura M, Nakao H, Yoshizaki H, Shiratsuchi M, Shigyo H, Yamada H, et al. Development of specific Rho-kinase inhibitors and their clinical application. Biochim Biophys Acta 2005; 1754: 245-252.
6. Miyagawa K, Emoto N. A new class of drug for pulmonary arterial hypertension: Can a Rho-kinase inhibitor break the stagnation in treating it? Circ J 2013; 77: 2477-2478.
7. Shimokawa H. Rho-kinase as a novel therapeutic target in treatment of cardiovascular disease. J Cardiovasc Pharmacol 2002; 39: 319-327.
8. Masato S, Shunsaku H, Minoru S, Shin-ichi S, Eiichi O, for the Fasudil Ischemic Stroke Study Group. Effects of fasudil in acute ischemic stroke: Results of a prospective placebo-controlled double-blind trial. J Neurol Sci 2005; 238: 31-39.
9. Ishikura K, Yamada N, Ito M, Ota S, Nakamura M, Isaka N, et al. Beneficial acute effects of Rho kinase inhibitor in patients with pul monary arterial hypertension. Circ J 2006; 70: 174-178.
10. Fujita H, Fukumoto Y, Saji K, Sugimura K, Demachi J, Nawata J, et al. Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension. Heart Vessels 2010; 25: 144-149.
11. Li F, Xia W, Yuan S, Sun R. Acute inhibition of Rho-kinase attenuates pulmonary hypertension in patients with congenital heart disease. Pediatr Cardiol 2009; 30: 363-366.
12. Doe Z, Fukumoto Y, Takaki A, Tawara S, Ohashi J, Nakano M, et al. Evidence for Rho-kinase activation in patients with pulmonary arterial hypertension. Circ J 2009; 73: 1731-1739.
13. Satoh K, Fukumoto Y, Shimokawa H. Rho-kinase: Important new therapeutic target in cardiovascular diseases. Am J Physiol Heart Circ Physiol 2011; 301: H287-H296.
14. Loirand G, Guerin P, Pacaud P. Rho kinases in cardiovascular physiology and pathophysiology. Circ Res 2006; 98: 322-334.
15. Fukumoto Y, Yamada N, Matsubara H, Mizoguchi M, Uchino K, Yao A, et al. Double-blind, placebo-controlled clinical trial with a rho-kinase inhibitor in pulmonary arterial hypertension. Circ J 2013; 77: 2619-2625.
16. Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T, et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 1997; 389: 990-994.
17. Somlyo AP, Somlyo AV. Signal transduction by G-proteins, rhokinase and protein phosphatase to smooth muscle and non-muscle myosin II. J Physiol 2000; 522: 177-185.
18. Hiroki J, Shimokawa H, Higashi M, Morikawa K, Kandabashi T, Kawamura N, et al. Inflammatory stimuli upregulate Rho-kinase inhuman coronary vascular smooth muscle cells. J Mol Cell Cardiol 2004; 37: 537-546.
19. Abe K, Shimokawa H, Morikawa K, Uwatoku T, Oi K, Matsumoto Y, et al. Long-term treatment with a Rho kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension. Circ Res 2004; 94: 385-393.
20. Fukumoto Y, Shimokawa H. Recent progress in the management of pulmonary hypertension. Circ J 2011; 75: 1801-1810.
21. Sharif Kashani B, Tahmaseb Pour P, Malekmohammad M, Behzadnia N, Sheybani-Afshar F, Fakhri M, et al. Oral l-citrulline malate in patients with idiopathic pulmonary arterial hypertension and Eisenmenger syndrome: A clinical trial. J Cardiol 2014; 64: 231-235.
22. Zhang DZ, Zhu XY, Meng J, Xue HM, Sheng XT, Han XM, et al. Acute hemodynamic responses to adenosine and iloprost in patients with congenital heart defects and severe pulmonary arterial hypertension. Int J Cardiol 2011; 147: 433-437.
23. Takemoto M, Sun J, Hiroki J, Shimokawa H, Liao JK. Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase. Circulation 2002; 106: 57-62.
24. Viswanathan S, Kumar RK. Assessment of operability of congenital cardiac shunts with increased pulmonary vascular resistance. Catheter Cardiovasc Interv 2008; 71: 665-670.